NKT cell depletion in humans during early HIV infection

Immunology and Cell Biology

Volumn 92, Issue 7, 2014, Pages 578-590

  Fernandez, Caroline S ^a   Kelleher, Anthony D ^b,c   Finlayson, Robert ^d   Godfrey, Dale I ^a   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c St Vincent's Centre for Applied Medical Research   (Australia)

^d Taylor Square Private Clinic ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD161 ANTIGEN; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; ALPHA-GALACTOSYLCERAMIDE; FC RECEPTOR; GALACTOSYLCERAMIDE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY B;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; NATURAL KILLER T CELL; PHENOTYPE; PROTEIN EXPRESSION; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; CASE CONTROL STUDY; DRUG EFFECTS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; GALACTOSYLCERAMIDES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; PHENOTYPE; RECEPTORS, IGG; T-LYMPHOCYTE SUBSETS;

EID: 84906066331     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.25     Document Type: Article

References (54)

1. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: What's in a name? Nat Rev Immunol 2004; 4: 231-237. (Pubitemid 38339089)
2. Godfrey DI, Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379-1388. (Pubitemid 40385565)
3. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11: 197-206.
4. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24\+ CD4-CD8-T cells. J Exp Med 1997; 186: 109-120.
5. Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 2010; 22: 68-78.
6. Gapin L, Godfrey DI, Rossjohn J. Natural Killer T cell obsession with self-antigens. Curr Opin Immunol 2013; 25: 168-173.
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336. (Pubitemid 46697911)
8. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, Barton N et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 2011; 208: 1163-1177.
9. Godfrey DI, Rossjohn J. New ways to turn on NKT cells. J Exp Med 2011; 208: 1121-1125.
10. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: An innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13: 101-117.
11. Schneiders FL, Scheper RJ, von Blomberg BM, Woltman AM, Janssen HL, van den Eertwegh AJ et al. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011; 140: 130-141.
12. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9: 28-38.
13. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 625-636. (Pubitemid 34461507)
14. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002; 195: 637-641. (Pubitemid 34461508)
15. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 2005; 35: 1399-1407. (Pubitemid 40691421)
16. Chan AC, Leeansyah E, Cochrane A, d'Udekem d'Acoz Y, Mittag D, Harrison LC et al. Ex vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(\+) and CD4(-) subsets. Clin Exp Immunol 2013; 172: 129-137.
17. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P et al. Selective loss of innate CD4(\+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 2002; 76: 7528-7534. (Pubitemid 34760975)
18. van der Vliet HJ, von Blomberg BM, Hazenberg MD, Nishi N, Otto SA, van Benthem BH et al. Selective decrease in circulating V alpha 24\+V beta 11\+ NKT cells during HIV type 1 infection. J Immunol 2002; 168: 1490-1495. (Pubitemid 34094524)
19. Crowe NY, Godfrey DI, Baxter AG. Natural killer T cells are targets for human immunodeficiency virus infection. Immunology 2003; 108: 1-2. (Pubitemid 36110857)
20. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002; 195: 869-879. (Pubitemid 34286758)
21. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ. Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol 2009; 83: 1617-1624.
22. Motsinger A, Azimzadeh A, Stanic AK, Johnson RP, Van Kaer L, Joyce S et al. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. J Virol 2003; 77: 8153-8158. (Pubitemid 36792811)
23. Rout N, Greene J, Yue S, O'Connor D, Johnson RP, Else JG et al. Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection. PLoS Pathogen 2012; 8: E1002928.
24. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, Sonnerborg A et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 2009; 39: 902-911.
25. Snyder-Cappione JE, Loo CP, Carvalho KI, Kuylenstierna C, Deeks SG, Hecht FM et al. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 2009; 23: 1965-1970.
26. van der Vliet HJ, van Vonderen MG, Molling JW, Bontkes HJ, Reijm M, Reiss P et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 2006; 177: 5775-5778. (Pubitemid 44628789)
27. Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, Tsuji M. Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol 2007; 19: 943-951. (Pubitemid 47386920)
28. Nowicki MJ, Vigen C, Mack WJ, Seaberg E, Landay A, Anastos K et al. Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses 2008; 24: 163-168. (Pubitemid 351282096)
29. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol 2010; 10: 11-23.
30. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006; 12: 289-295. (Pubitemid 43355074)
31. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371. (Pubitemid 44924494)
32. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888. (Pubitemid 37070273)
33. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169: 3400-3406. (Pubitemid 35013190)
34. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K et al. Relationship between T cell activation and CD4\+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133. (Pubitemid 351263476)
35. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870. (Pubitemid 29159331)
36. Baev DV, Peng XH, Song L, Barnhart JR, Crooks GM, Weinberg KI et al. Distinct homeostatic requirements of CD4\+ and CD4-subsets of Valpha24-invariant natural killer T cells in humans. Blood 2004; 104: 4150-4156.
37. Uciechowski P, Werfel T, Leo R, Gessner JE, Schubert J, Schmidt RE. Analysis of CD16\+dim and CD16\+bright lymphocytes-comparison of peripheral and clonal non-MHC-restricted T cells and NK cells. Immunobiology 1992; 185: 28-40.
38. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3\+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med 1985; 162: 2089-2106. (Pubitemid 16149696)
39. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ. Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 2006; 80: 164-173. (Pubitemid 44835537)
40. Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol 2008; 127: 1-6.
41. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P et al. Plasma viral load and CD4\+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954. (Pubitemid 27255797)
42. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y et al. Tcell activation in HIV-seropositive Ugandans: Differential associations with viral load, CD4\+ T cell depletion, and coinfection. J Infect Dis 2005; 191: 694-701. (Pubitemid 40271056)
43. Ibarrondo FJ, Wilson SB, Hultin LE, Shih R, Hausner MA, Hultin PM et al. Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection. Mucosal Immunol 2013; 6: 591-600.
44. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 2010; 116: 1876-1884.
45. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171: 4020-4027. (Pubitemid 37238677)
46. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100: 10913-10918. (Pubitemid 37140127)
47. O'Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, Jackson J et al. Distinct and overlapping effector functions of expanded human CD4\+, CD8alpha\+ and CD4-CD8alpha-invariant natural killer T cells. PLoS ONE 2011; 6: E28648.
48. Gadola SD, Dulphy N, Salio M, Cerundolo V. Valpha24-JalphaQ-independent, CD1drestricted recognition of alpha-galactosylceramide by human CD4(\+) and CD8alphabeta(\+) T lymphocytes. J Immunol 2002; 168: 5514-5520.
49. Brigl M, van den Elzen P, Chen X, Meyers JH, Wu D, Wong CH et al. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors. J Immunol 2006; 176: 3625-3634. (Pubitemid 43364010)
50. Fernandez CS, Cameron G, Godfrey DI, Kent SJ. Ex vivo alpha-galactosylceramide activation of NKT cells in humans and macaques. J Immunol Methods 2012; 382: 150-159.
51. Yang OO, Wilson SB, Hultin LE, Detels R, Hultin PM, Ibarrondo FJ et al. Delayed reconstitution of CD4\+ iNKT cells after effective HIV type 1 therapy. AIDS Res Hum Retroviruses 2007; 23: 913-922. (Pubitemid 47267500)
52. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis. Cell Death Dis 2010; 1: E99.
53. Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T et al. Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death. Oncogene 1998; 17: 1475-1482. (Pubitemid 28458416)
54. Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: Implications for HIV-1 vaccine design. J Virol 2008; 82: 7700-7710. (Pubitemid 352031235)